FDA Approves Talzenna for Metastatic, Castration-Resistant Prostate Cancer

MONDAY, June 26, 2023 -- The U.S. Food and Drug Administration has approved Talzenna (talazoparib) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
The approval was...